dorzolamide/timolol eg 20 mg/ml - 5 mg/ml eye drops sol. dropper cont.
eg sa-nv - timolol maleate 6,83 mg/ml - eq. timolol 5 mg/ml; dorzolamide hydrochloride 22,26 mg/ml - eq. dorzolamide 20 mg/ml - eye drops, solution - 20 mg/ml - 5 mg/ml - timolol maleate 6.83 mg/ml; dorzolamide hydrochloride 22.26 mg/ml - timolol, combinations
dorzolamide/timolol sandoz 20 mg/ml - 5 mg/ml eye drops sol. dropper cont.
sandoz sa-nv - dorzolamide hydrochloride 22,26 mg/ml - eq. dorzolamide 20 mg/ml; timolol maleate 6,83 mg/ml - eq. timolol 5 mg/ml - eye drops, solution - 20 mg/ml - 5 mg/ml - dorzolamide hydrochloride 22.26 mg/ml; timolol maleate 6.83 mg/ml - timolol, combinations
ag-dorzolamide timolol solution
angita pharma inc. - timolol (timolol maleate); dorzolamide (dorzolamide hydrochloride) - solution - 5mg; 20mg - timolol (timolol maleate) 5mg; dorzolamide (dorzolamide hydrochloride) 20mg
misopt eye drops ophthalmic solution
micro labs limited #31, race course road, bangalore 560 001 - dorzolamide hydrochloride and timolol maleate - ophthalmic solution - 2%w/v dozolamide and 0.5%w/v timolol - timolol combinations
dorzolamide/timolol
actavis group ptc ehf - dorzolamide ; timolol - eye drops solution - 20+5 mg/ml - timolol, combinations
trusopt
rafa laboratories ltd - dorzolamide as hydrochloride - ophthalmic solution - dorzolamide as hydrochloride 20 mg/ml - dorzolamide - dorzolamide - for the treatment of eleveated intraocular pressure in patients with ocular hypertension, open-angle glaucoma and in some patients secondary glaucoma.
zolichek - t ophthalmic solution eye drops
indoco remedies limited "l-32, 33 & 34 verna industrial area, verna, goa, - dorzolamide hydrochloride timolol maleate - eye drops - "dorzolamide hydrochloride.20 mg timolol maleate - ophthalmological antiglaucoma preparations and
dorzolamide/timolol mylan 20+5 mg/ml eye drops solution
mcdermott laboratories ltd t/a gerard laboratories - dorzolamide hydrochloride timolol maleate - eye drops solution - 20+5 mg/ml
dorzolamide hcl solution/ drops
bausch & lomb incorporated - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 20 mg in 1 ml - dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. dorzolamide hydrochloride ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.1)] . risk summary there are no adequate and well-controlled studies in pregnant women with dorzolamide hydrochloride ophthalmic solution. dorzolamide caused fetal vertebral malformations when administered orally to rabbits at 2.5 mg/kg/day (37 times the clinical exposure). dorzolamide administered during the period of organogenesis was not teratogenic in rabbits dosed up to 1 mg/kg/day (15 times the clinical exposure). dorzolamide hydrochloride administered orally to rats during late gestation and lactation caused growth delays in offspring at 7.5 mg/kg/day (52 times the clinical exposure). growth was not delayed at 1 mg/kg/day (8.0 times the clinical exposure). the background r
dorzolamide hydrochloride solution/ drops
sandoz inc - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 20 mg in 1 ml - dorzolamide hydrochloride ophthalmic solution, 2% is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. dorzolamide hydrochloride ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.1)]. there are no adequate and well-controlled studies in pregnant women with dorzolamide hydrochloride ophthalmic solution. dorzolamide caused fetal vertebral malformations when administered orally to rabbits at 2.5 mg/kg/day (37 times the clinical exposure). dorzolamide administered during the period of organogenesis was not teratogenic in rabbits dosed up to 1 mg/kg/day (15 times the clinical exposure). dorzolamide hydrochloride administered orally to rats during late gestation and lactation caused growth delays in offspring at 7.5 mg/kg/day (52 times the clinical exposure). growth was not delayed at 1 mg/kg/day (8.0 times the clinical exposure). the background risk of maj